Ipca Laboratories has entered into a technology transfer agreement with fellow Indian firm Omexa Formulary, granting Omexa non-exclusive rights to research, develop, manufacture and market an oncology biosimilar for the global market.
“This agreement shall enable Omexa to develop this anti-cancer biosimilar from early stage of development to clinical trials and subsequent commercial launch,” Ipca noted, adding that it would
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?